EssilorluxotticaXSWX:EI 85 EBITDA Margin % is 20.67% as of Dec. 2025, which is 12% below its 10-year median of 23.46. GuruFocus rates XSWX:EI with a GF Score™ of 85/100 and a GF Value™ of CHF159.01. The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Essilorluxottica ranks better than 81.37% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Essilorluxottica's EBITDA for the
six
months ended in Dec. 2025 was CHF2,791 Mil. Essilorluxottica's Revenue for the
six
months ended in Dec. 2025 was CHF13,500 Mil. Therefore, Essilorluxottica's EBITDA margin for the quarter that ended in Dec. 2025 was 20.67%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Essilorluxottica EBITDA Margin % Related Terms
Essilorluxottica EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Essilorluxottica's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:EI vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Essilorluxottica's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essilorluxottica EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Essilorluxottica's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Essilorluxottica's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Essilorluxottica (XSWX:EI) has a EBITDA Margin % of 20.67% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Essilorluxottica and its competitors. This is 12% below median its historical median of 23.46. Over the past decade, Essilorluxottica's EBITDA Margin % has ranged from 18.08 to 24.94. According to the industry distribution chart, Essilorluxottica ranks #152 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 18.6%.
Is Essilorluxottica's EBITDA Margin % too high?
Essilorluxottica's current EBITDA Margin % of 20.67% is 12% below median its 10-year median of 23.46. Over the past 10 years, this metric has ranged from a low of 18.08 to a high of 24.94. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Essilorluxottica's value of 20.67% is 176.5% above this industry median. Based on the distribution chart, Essilorluxottica ranks #152 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Essilorluxottica has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Essilorluxottica's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Essilorluxottica ranks #152 out of 816 companies for EBITDA Margin %. This places Essilorluxottica in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Essilorluxottica's value of 20.67% is 176.5% above this benchmark. Historically, Essilorluxottica's own EBITDA Margin % has ranged from 18.08 to 24.94 over the past decade. While the company's 10-year median is 23.46 vs. the industry median of 7.48, Essilorluxottica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essilorluxottica's current EBITDA Margin % of 20.67% is 176.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Essilorluxottica and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essilorluxottica's current EBITDA Margin % is 20.67%, which is 12% below median its own 10-year median of 23.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essilorluxottica stock overvalued right now?
Essilorluxottica (XSWX:EI) has a current EBITDA Margin % of 20.67%. The stock's GF Value™ is CHF159.01, compared to a current price of CHF117.00 — trading 26.4% below its estimated fair value. The current EBITDA Margin % is 20.67%, which is 12% below median its 10-year median of 23.46 and 176.5% above the Medical Devices & Instruments industry median of 7.48. Essilorluxottica's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Essilorluxottica (XSWX:EI), the current EBITDA Margin % is 20.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essilorluxottica (XSWX:EI) Overvalued in 2026?
Based on GuruFocus' analysis, Essilorluxottica stock appears to be undervalued.
The current stock price of CHF117.00 is trading 26.4% below its estimated GF Value™ of CHF159.01.
Key valuation signals for XSWX:EI:
EBITDA Margin %: 20.67% (12% below median its 10-year median of 23.46)
GF Value™: CHF159.01 vs. price of CHF117.00 (26.4% below fair value)
Industry Position: 176.5% above the Medical Devices & Instruments median (#152 of 816)
No single metric tells the full story. See the XSWX:EI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EssilorLuxottica is a combination of the leading manufacturer of premium frames and sunglasses and the leading manufacturer of optical lenses. Both companies are significantly larger than the next biggest competitor and command over 15% of the fragmented global eyewear market. The company has a broad geographical presence, with around 37% of sales in Europe, 45% in North America, and the rest in Asia and Latin America.
85GF Score
Get the complete analysis for XSWX:EI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EI has been successfully added to your 
